Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Custirsen plus docetaxel versus docetaxel in second-line stage IV non-small cell lung cancer
2012-002447-14Phase 3Terminated
- Sponsor
- Achieve Life Sciences
- Start
- Oct 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Custirsen + docetaxel with Docetaxel (2 arms). Primary endpoint: Overall survival. Started Oct 2012; status: terminated.
02
Drugs
custirsendocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-002447-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002447-14.